News & Articles

Featured Article

Nanodiscs: A Versatile Platform for Membrane Protein Research

Membrane proteins are essential to numerous cellular processes and represent more than half of all current drug targets—yet they remain some of the most difficult proteins to studyin vitrodue to their dependence on the lipid bilayer. Traditional approaches often rely on detergents...

Browse articles by topic:

The New Frontier in SCLC Treatment: 4 Antigens Driving Antibody Innovation

The New Frontier in SCLC Treatment: 4 Antigens Driving Antibody Innovation

June 25, 2025

9 min read

STEAP1: The Next Blockbuster Target for Prostate Cancer

STEAP1: The Next Blockbuster Target for Prostate Cancer

June 16, 2025

5 min read

Targeted Therapies for Inflammatory Bowel Disease (IBD)

Targeted Therapies for Inflammatory Bowel Disease (IBD)

May 28, 2025

6 min read

The Landscape of GPCR-targeting Antibody Drug Development

The Landscape of GPCR-targeting Antibody Drug Development

May 9, 2025

9 min read

For Better Symptom Relief: Targeted Therapy for Asthma

For Better Symptom Relief: Targeted Therapy for Asthma

April 15, 2025

11 min read

At the Crossroads of Metabolic and Cancer Therapeutics — GDF15

At the Crossroads of Metabolic and Cancer Therapeutics — GDF15

April 1, 2025

7 min read

NPR1: Major Drug Target for Heart Failure

NPR1: Major Drug Target for Heart Failure

February 25, 2025

5 min read

Immunotherapy Target: CD19 Antigen

Immunotherapy Target: CD19 Antigen

February 4, 2025

7 min read

Case Review: Exploring domain proteins in antibody development

Case Review: Exploring domain proteins in antibody development

January 22, 2025

8 min read

GDF-8 (Myostatin) antibody Apitegromab achieves success in Phase III clinical trial

GDF-8 (Myostatin) antibody Apitegromab achieves success in Phase III clinical trial

June 13, 2024

4 min read

MSLN Targeted Drugs Entering the Fast Lane

MSLN Targeted Drugs Entering the Fast Lane

February 29, 2024

5 min read

New target for colorectal cancer: GPA33

New target for colorectal cancer: GPA33

February 24, 2023

4 min read

Potential drug target for tumors: CDCP1

Potential drug target for tumors: CDCP1

February 21, 2023

6 min read

Focus on Hematoma Target Fms-like Tyrosine Kinase 3 (FLT3)

Focus on Hematoma Target Fms-like Tyrosine Kinase 3 (FLT3)

January 9, 2023

6 min read

DKK1: A Wnt Pathway Regulator

DKK1: A Wnt Pathway Regulator

January 6, 2023

5 min read

1 2 →

The Rise of Allogeneic Cell Therapies: Strategies, Challenges, and Clinical Advances

The Rise of Allogeneic Cell Therapies: Strategies, Challenges, and Clinical Advances

April 8, 2025

7 min read

CDH17: A Safe CAR-T Target for Treatment of Solid Tumors

CDH17: A Safe CAR-T Target for Treatment of Solid Tumors

July 19, 2022

5 min read

TM4SF1 in Cancer Immunotherapy: Emerging Research and Clinical Potential

TM4SF1 in Cancer Immunotherapy: Emerging Research and Clinical Potential

September 5, 2022

5 min read

The History of Refolding MHCs: Building MHC Molecules from the Ground Up

The History of Refolding MHCs: Building MHC Molecules from the Ground Up

October 6, 2025

5 min read

Expanding Landscape of TCR Therapies: Clinical Breakthroughs, Formats, and Production Support

Expanding Landscape of TCR Therapies: Clinical Breakthroughs, Formats, and Production Support

June 12, 2025

5 min read

Cracking KRAS: How TCR-T and TCR-Mimic Antibodies Are Changing KRAS Mutant Cancers

Cracking KRAS: How TCR-T and TCR-Mimic Antibodies Are Changing KRAS Mutant Cancers

March 18, 2025

10 min read

Rethinking Refolding: The Case for Mammalian-Expressed Single-Chain Trimer MHCs

Rethinking Refolding: The Case for Mammalian-Expressed Single-Chain Trimer MHCs

September 18, 2024

5 min read

Neoantigen-Based Immunotherapy: Unveiling Disease-Specific Targets

Neoantigen-Based Immunotherapy: Unveiling Disease-Specific Targets

August 20, 2024

4 min read

Butyrophilin (BTN) family: γδ T Cell Receptor Ligands, Immunomodulators and More

Butyrophilin (BTN) family: γδ T Cell Receptor Ligands, Immunomodulators and More

December 27, 2023

5 min read

Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

December 20, 2023

Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Transforming Tumor Research: Engineering MHCs as Versatile Reagents

September 7, 2023

1 min read

Cell and Antibody Therapies Targeting HLA-G

Cell and Antibody Therapies Targeting HLA-G

February 14, 2023

3 min read

TCR Therapy Targeting MAGE-A4

TCR Therapy Targeting MAGE-A4

January 2, 2023

1 min read

Rewriting Life's Code: CRISPR Precisely Edits Blood Disorder Defects

Rewriting Life's Code: CRISPR Precisely Edits Blood Disorder Defects

August 5, 2025

3 min read

AAV Capsid Optimization and Precision Quantification: Customized AAV ELISA Detection Solutions

AAV Capsid Optimization and Precision Quantification: Customized AAV ELISA Detection Solutions

June 4, 2025

2 min read

Ensuring Safe and Effective Gene Therapy with Precise AAV Capsid Quantification

Ensuring Safe and Effective Gene Therapy with Precise AAV Capsid Quantification

March 25, 2025

6 min read

Breaking News: KACTUS GMP-Grade Cas9 Powers Bioheng’s Breakthrough IND Clearance for Next-Gen UCAR-T Therapy

Breaking News: KACTUS GMP-Grade Cas9 Powers Bioheng’s Breakthrough IND Clearance for Next-Gen UCAR-T Therapy

March 5, 2025

4 min read

Effective Serratia marcescens Nuclease for DNA & RNA Removal: MaxNuclease™

Effective Serratia marcescens Nuclease for DNA & RNA Removal: MaxNuclease™

February 21, 2025

3 min read

Panorama of CRISPR Gene Editing Clinical Applications: 2024 Review

Panorama of CRISPR Gene Editing Clinical Applications: 2024 Review

January 31, 2025

8 min read

NK Cell Therapy Gets IND FDA Clearance with AccuBase® Base Editor from KACTUS

NK Cell Therapy Gets IND FDA Clearance with AccuBase® Base Editor from KACTUS

November 21, 2024

5 min read

2024 Milestones in CRISPR Clinical Pipelines

2024 Milestones in CRISPR Clinical Pipelines

November 11, 2024

5 min read

Base Editing vs. CRISPR: Navigating Precision Gene Therapy

Base Editing vs. CRISPR: Navigating Precision Gene Therapy

October 14, 2024

5 min read

AccuBase™ Base Editor Continues to Advance NK Cell Therapies

AccuBase™ Base Editor Continues to Advance NK Cell Therapies

July 31, 2024

4 min read

IND Approval for Solid Tumor Therapy Using KACTUS Cas9 Enzyme

IND Approval for Solid Tumor Therapy Using KACTUS Cas9 Enzyme

July 24, 2024

4 min read

Gene Editing Drugs from the EMA Review Perspective

Gene Editing Drugs from the EMA Review Perspective

June 25, 2024

5 min read

FDA New Guidelines Pave the Way for Gene Editing Drug Development

FDA New Guidelines Pave the Way for Gene Editing Drug Development

April 24, 2024

2 min read

Base Editing Technology Leads a New Chapter in Drug Development

Base Editing Technology Leads a New Chapter in Drug Development

February 14, 2024

5 min read

Exploring RNP: A Cutting-Edge Tool for Gene Delivery

Exploring RNP: A Cutting-Edge Tool for Gene Delivery

February 2, 2024

5 min read

1 2 →

Beyond GLP-1: ALK7–Activin E as a More Targeted Approach to Obesity Therapy

Beyond GLP-1: ALK7–Activin E as a More Targeted Approach to Obesity Therapy

December 15, 2025

7 min read

GDF-8: A New Era in Muscle Growth Therapies is Coming to Market

GDF-8: A New Era in Muscle Growth Therapies is Coming to Market

December 9, 2025

4 min read

KLK2: The New Promising Target for Prostate Cancer

KLK2: The New Promising Target for Prostate Cancer

December 4, 2025

4 min read

CDCP1: A New Therapeutic Target for Malignant Tumors

CDCP1: A New Therapeutic Target for Malignant Tumors

November 26, 2025

6 min read

IgE: The Key Therapeutic Target for Allergy Treatment

IgE: The Key Therapeutic Target for Allergy Treatment

November 20, 2025

7 min read

CDH17: The Next Breakthrough in Gastrointestinal Cancer Therapy

CDH17: The Next Breakthrough in Gastrointestinal Cancer Therapy

November 12, 2025

7 min read

FcRh5: An Emerging Therapeutic Target in Multiple Myeloma

FcRh5: An Emerging Therapeutic Target in Multiple Myeloma

October 22, 2025

7 min read

BAFF and APRIL: Key Targets in Autoimmune Diseases and a Review of Dual- and Single-Target Inhibitors

BAFF and APRIL: Key Targets in Autoimmune Diseases and a Review of Dual- and Single-Target Inhibitors

August 13, 2025

8 min read

A New Era in Targeted Therapies: Ichnos Glenmark Innovation and AbbVie Blaze a Trail with Tri-specific Antibodies

A New Era in Targeted Therapies: Ichnos Glenmark Innovation and AbbVie Blaze a Trail with Tri-specific Antibodies

July 29, 2025

3 min read

KACTUS Unveils Ultra-low Endotoxin Recombinant Protein Line — Powering Cleaner, Faster, Smarter Drug Discovery

KACTUS Unveils Ultra-low Endotoxin Recombinant Protein Line — Powering Cleaner, Faster, Smarter Drug Discovery

July 10, 2025

1 min read

Why Endotoxin Testing Matters: Safeguarding Recombinant Protein Applications in Immunology and Drug Discovery

Why Endotoxin Testing Matters: Safeguarding Recombinant Protein Applications in Immunology and Drug Discovery

May 22, 2025

4 min read

MASP2 Antibody Successful in Phase III Clinical Trial

MASP2 Antibody Successful in Phase III Clinical Trial

February 10, 2025

5 min read

Emerging New Therapeutic Targets for Obesity

Emerging New Therapeutic Targets for Obesity

January 14, 2025

7 min read

Targeting Obesity: GLP-1R/GIPR, GDF8 Leading the Way

Targeting Obesity: GLP-1R/GIPR, GDF8 Leading the Way

December 10, 2024

7 min read

Activin Signaling Pathway: Therapeutic Potential Across Disease Frontiers

Activin Signaling Pathway: Therapeutic Potential Across Disease Frontiers

November 25, 2024

7 min read

1 2 3 →

Optimizing Large-scale Circular RNA Production Process with KACTUS Engineered RNase R

Optimizing Large-scale Circular RNA Production Process with KACTUS Engineered RNase R

March 13, 2025

9 min read

Case Study: KACTUS T7 RNA Polymerase Enzyme Demonstrates Superior Performance in Independent Study

Case Study: KACTUS T7 RNA Polymerase Enzyme Demonstrates Superior Performance in Independent Study

February 7, 2025

4 min read

The Ideal Choice for Low dsRNA: MaxPure™ T7 RNA Polymerase

The Ideal Choice for Low dsRNA: MaxPure™ T7 RNA Polymerase

July 16, 2024

7 min read

Engineered T7 RNA Polymerase to Reduce dsRNA

Engineered T7 RNA Polymerase to Reduce dsRNA

May 24, 2023

1 min read

Full Portfolio of In Vitro mRNA Synthesis Enzymes Submitted to FDA Drug Master Files (DMF)

Full Portfolio of In Vitro mRNA Synthesis Enzymes Submitted to FDA Drug Master Files (DMF)

April 23, 2023

2 min read

BsaI and T7 RNA Polymerase of KACTUS Pass FDA DMF Filing

BsaI and T7 RNA Polymerase of KACTUS Pass FDA DMF Filing

January 4, 2023

2 min read

Base Therapeutics and KACTUS Announce Strategic Partnership with Synthego to Advance GMP AccuBase™ Base Editing Platform

Base Therapeutics and KACTUS Announce Strategic Partnership with Synthego to Advance GMP AccuBase™ Base Editing Platform

October 28, 2025

3 min read

KLK5/7: Emerging Targets for Inflammatory Skin Diseases

KLK5/7: Emerging Targets for Inflammatory Skin Diseases

October 27, 2025

6 min read

Optimizing Large-scale Circular RNA Process with KACTUS Engineered RNase R

Optimizing Large-scale Circular RNA Process with KACTUS Engineered RNase R

October 14, 2025

9 min read

The Notorious KRAS

The Notorious KRAS

September 16, 2025

10 min read

The Silent Saboteur: Endotoxin Contamination and Its Impact on Your Research Data

The Silent Saboteur: Endotoxin Contamination and Its Impact on Your Research Data

September 10, 2025

5 min read

The Story of the New KACTUS Logo: Design and Symbolism

March 19, 2022

2 min read

Have questions? Get in touch!

support@kactusbio.us

Latest Biotech News & Updates - KACTUS Research Insights

↑